Prenatal screening of fetal disease with triple marker program: Determination of AFP, BHcG and E3 in maternal serum
Article
Acuna, JM, De Elejalde, MM, Elejalde, BR et al. (1994). Prenatal screening of fetal disease with triple marker program: Determination of AFP, BHcG and E3 in maternal serum
. 45(1), 39-45.
Acuna, JM, De Elejalde, MM, Elejalde, BR et al. (1994). Prenatal screening of fetal disease with triple marker program: Determination of AFP, BHcG and E3 in maternal serum
. 45(1), 39-45.
Determination of the abnormal fetuses has been done using maternal age and previous family history, detecting only a small percentage of abnormal fetuses. Introduction of biochemical maternal serum substances (AFP, BHcG, uE3), has provided a useful tool to determine a high percentage (54% to 67%) of abnormal fetuses/gestations of those woman who do not have other indications to undergo complete prenatal diagnosis. So far, the limitations of this program are the standarization of the absolute values, the interpretation of the values with complex and expensive computer programs and the clinical interpretation of those values. This review gives the current application and concepts involved in the Triple Marker Screening.
